<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To evaluate the addition of a third drug to standard induction chemotherapy in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 23 patients (males/females 13/10, median age 54.3 years, range 24-74 years, median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> duration 9.8 months, range 2-39 months) who received a standard 2-drugs induction were compared with 23 patients (males/females 11/12, median age 45.6 months, range 21-60 years, median <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> duration 8.3 months, range 2-29 months) who received an intensified 3-drugs induction with <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>CR rate, median CR duration and median OS were similar in both groups (48% vs 56%, 4.8 vs 5.9 months, 6.5 vs 7.0 months respectively) </plain></SENT>
<SENT sid="2" pm="."><plain>Among responding patients, <z:hpo ids='HP_0000001'>all</z:hpo> but one, who underwent allogeneic bone marrow transplantation, relapsed </plain></SENT>
<SENT sid="3" pm="."><plain>In conclusion, addition of a third drug (<z:chebi fb="0" ids="4911">etoposide</z:chebi>) does not seem to significantly improve the poor prognosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
</text></document>